bluebird bio (BLUE) Granted FDA Priority Review of Biologics License Application for eli-cel Gene Therapy
Go back to bluebird bio (BLUE) Granted FDA Priority Review of Biologics License Application for eli-cel Gene Therapy| BLUEBIRD BIO (NASDAQ: BLUE) | Delayed: 0.92 -0.05 (5.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.97 | 52 Week High | $95.28 | |||
| Open | $0.99 | 52 Week Low | $35.37 | |||
| Day High | $1.02 | P/E | N/A | |||
| Day Low | $0.91 | EPS | $-1.81 | |||
| Volume | 8,136,299 | |||||
